Zacks Investment Research upgraded shares of Lion Biotech (GNBP) from N/A to OUTPERFORM on January 13, 2014, with a target price of $20.00.
LBIO is an emerging biotech company focused on TILs for the treatment of cancer. TILs have demonstrated compelling efficacy and safety profile in metastatic melanoma patients in physician sponsored clinical trials. We are optimistic about the prospect of TILs technology for the treatment of melanoma and other solid tumors. Lion plans to move TILs to pivotal trials soon and also plans to develop second generation of TILs for cheaper and better product. Balance sheet remains strong and valuation is attractive at this time.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Lion Biotech (GNBP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment